Drugs / HS627
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05323981 | Apr → Oct 2022 | — | BioRay Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04820439 | Oct 2020 → Feb 2021 | — | The Affiliated Hospital of Qingdao University | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04514419 | Jun 2020 → Sep 2024 overdue | breast cancer | BioRay Pharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HS627 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04514419 ↗ |
| Modality | Monoclonal antibody | “recombinant monoclonal antibody against human epidermal growth factor receptor injection (HS627)” NCT04820439 ↗ |
| Route | Intravenous | “A single intravenous infusion of HS627 420mg” NCT04820439 ↗ |